Sangamo Therapeutics (SGMOQ) Receivables - Other (2010 - 2024)

Sangamo Therapeutics has reported Receivables - Other for 15 years, with the latest figure at $10.0 million in Q3 2024.

• On a quarterly basis, Receivables - Other rose 1561.13% year-over-year to $10.0 million in Q3 2024; TTM through Sep 2024 was $10.0 million, a 1561.13% increase from a year earlier, with the FY2023 full-year figure at $403000.0, down 49.24% from the prior year.
• Receivables - Other was $10.0 million for Q3 2024 at Sangamo Therapeutics, up from $403000.0 in the prior quarter.
• The five-year high for Receivables - Other was $10.0 million in Q3 2024, with the low at $289000.0 in Q2 2022.
• Average Receivables - Other over 5 years is $1.3 million, with a median of $794000.0 recorded in 2022.
• The sharpest annual moves came in 2021 and 2024: Receivables - Other tumbled 66.28% in 2021, then soared 1561.13% in 2024.
• Over 5 years, Receivables - Other stood at $1.0 million in 2020, then tumbled by 66.28% to $349000.0 in 2021, then surged by 127.51% to $794000.0 in 2022, then sank by 49.24% to $403000.0 in 2023, then surged by 2381.39% to $10.0 million in 2024.
• The last three Receivables - Other figures came in at $10.0 million (Q3 2024), $403000.0 (Q4 2023), and $602000.0 (Q3 2023), per Business Quant data.